By Kashish Tandon and Rishika Sadam HYDERABAD/BENGALURU (Reuters) -Sun Pharmaceutical, India's largest drugmaker by revenue, ...

Sun Pharma reported a 15% YoY rise in Q3FY25 profit to Rs 2,903 crore, surpassing estimates. Revenue grew 10% to Rs 13,675.5 ...

Out of the 41 analysts that have coverage on Sun Pharma, 30 of them have a 'Buy' rating on the stock. Seven of them have a ...

Net Sales at Rs 13,675.46 crore in December 2024 up 10.46% from Rs. 12,380.70 crore in December 2023. Quarterly Net Profit at ...

Net Sales at Rs 6,191.81 crore in December 2024 up 22.04% from Rs. 5,073.75 crore in December 2023. Quarterly Net Profit at ...

Results: Sun Pharmaceutical Industries on Friday said its consolidated net profit increased 15 per cent on-year to Rs 2,903 ...

Sun Pharmaceutical Industries reported a 15% rise in net profit for the December quarter, driven by strong global sales. The ...

Stay updated with the Sun Pharma Stock Liveblog, your one-stop destination for real-time information and analysis of a ...

Sun Pharmaceutical Industries Ltd. closed 11.08% below its 52-week high of 1,960.20 rupees, which the company achieved on September 30th.

Sun Pharma's Q3FY25 net profit rose 15% YoY to ₹2,903 crore, driven by strong domestic and global specialty sales. Revenue ...

Sun Pharmaceutical Industries Ltd. reported consolidated net profit rose 15% to ₹2,903 crore for the third quarter ended December 31, 2024 from ₹2,524 crore a year earlier. Gross sales during the ...

Sun Pharmaceutical , India's largest drugmaker by revenue, reported a bigger-than-expected quarterly profit on Friday, aided ...